Biopharma is entering its second-quarter earnings season riding high on a wave of massive deals and venture capital flow, plus a clearing of regulatory and policy overhangs. What can industry watchers expect to hear on the upcoming investor calls?
Q2 earnings arrive as pharma picks up steam, buoyed by dealmaking, policy tailwinds